QED Bioscience

QED Bioscience is a commercial-stage life science tools company focused on antibodies, antigens, recombinant proteins, assay reagents, and custom antibody development services for academic, biotechnology, diagnostic, and pharmaceutical customers. The company has historically operated as a full-spectrum antibody provider, offering monoclonal and polyclonal antibodies, immunochemistry services, purification and conjugation, peptide synthesis, ELISA-related services, and cell culture support. Its catalog and custom capabilities are used primarily in research and in vitro diagnostic assay development rather than therapeutic drug development. In September 2024, QED Bioscience was acquired by Leinco Technologies and now operates as part of Leinco's broader research antibody and IVD raw materials business. The company's product focus spans infectious disease, oncology, neuroscience, and therapeutic drug monitoring applications.